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| INTRODUCTION
Von Willebrand factor (VWF) is a complex multimeric protein of 500 kDa to 20 MDa molecular weight (MW) that circulates in plasma and is stored in platelet α-granules and endothelial cell Weibel-Palade bodies. 1 Not only does VWF serve as the carrier protein of circulating factor VIII (FVIII), preventing its proteolytic degradation, 2 its chief function is to mediate platelet adhesion to extracellular matrix components exposed by wounding. 3 Binding to the platelet GP Ib/IX/V receptor complex occurs via the VWF-A1 domain and to type III and VI collagens exposed at the wound site through the VWF-A3 domain. 4, 5 Shear conditions and immobilization of VWF are required to induce conformational changes that increase its affinity for the GPIb complex. 6 The ultra large and high MW forms of VWF multimers, derived from plasma and endothelial cells, are most efficient at mediating platelet adhesion to collagen surfaces. In order to evaluate their clinical efficacy, many previous studies have compared the VWF content of commercially available concentrates in terms of the standard laboratory measure of activity such as ristocetin cofactor activity (VWF:RCo) and collagen binding activity (VWF:CB) performed under static conditions, as well as VWF multimer distribution. [10] [11] [12] [13] [14] [15] However, relatively few studies have addressed the functionality of these concentrates in terms of their ability to mediate platelet adhesion to collagen surfaces under physiological shear conditions. 16 In this study we have assessed the effect of ten commercially available VWF containing concentrates on platelet adhesion to collagen under shear stress using an in vitro assay. These results were compared with conventional assessment of VWF function assessed by VWF antigen (VWF:Ag), VWF:RCo, VWF:CB, and VWF multimeric analysis. Haemoctin) and then further serially diluted for the respective assay.
| MATERIALS AND METHODS

| VWF concentrates
Each sample dilution was assayed in duplicate in five separate assays.
One stage APTT based FVIII:C levels were measured on an ACL TOP 700 coagulometer (Instrumentation Laboratory, (Bedford, MA). All assays have been previously published. 17 
Essentials
• VWF-containing concentrates are commonly used to treat VWD.
• The activity of 10 VWF concentrates were investigated under static and flow conditions.
• Differences were observed in free-thiol and ADAMTS13 content and multimeric profile and the initial extent of platelet capture.
• Overall platelet capture did not differ between concentrates suggesting equal effectiveness. with ABC alkaline phosphatase kit (Vectastain). VWF multimer gels were visually compared to a reference "normal pooled plasma" sample. Densitometric analysis was performed essentially as previously described using ImageJ software. 18 In brief, individual peaks on the densitometry plot were counted from the dimer band up to the tenth peak (representing the 10-mer), everything beyond the 10-mer was designated as being one high molecule weight peak. The pixel area under the 10-mer peak was quantified and taken as a percentage of the total area under the full densitometry scan.
| VWF multimeric profiles
| Total protein measurement
Total protein content of each VWF concentrate was assayed using a commercially available Bradford reagent as per the manufacturer's instructions (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK).
| In vitro flow assay
Platelet adhesion to collagen-coated flow chamber slides and preparation of washed platelets and red blood cells (RBCs)
were performed essentially as previous described. 19 In brief, 
| Assessment of VWF glycosylation
To As a control to ensure equivalent capture wells were also incubated with anti-VWF-HRP antibodies. Sigma colourfast OPD substrate was added to the wells and following stopping with 2 mol/L H 2 SO 4 wells were read at 492 nm.
| Assay for VWF-free thiols
The free-thiol content of each concentrate was determined essentially as previous described. 20 In brief 1 U/mL of each VWF concentrate was 
| Measurement of ADAMTS-13
Plasma ADAMTS13 was measured using an "in-house" ADAMTS13
ELISA as previously described. 
| Statistical analysis
Statistical analysis was performed using Prism7 software, using a standard one-way ANOVA with multiple comparisons.
| RESULTS
| FVII & VWF laboratory parameters from the nine commercially available concentrates
The laboratory parameters of all 10 VWF concentrates measured after reconstitution according to the manufacturers' instructions are summarized in Table 1 
| Lectin analysis of VWF concentrates
All the concentrates tested had similar binding to the four lectins (Con A, EBL, RCA-1, and GNL) confirming the presence of N-linked glycan chains, a similar sialic acid content, terminal galactose and high mannose content respectively ( Figure 1 ). MAL-II binds to sialic acid but prefers α2-3 linked resides that are more predominant on Olinked glycans. 8Y showed significantly reduced MAL-II binding and this was combined with a significant increase in binding to PNA, that recognizes the desialyted T-antigen O-linked glycan structure previously shown to be present on VWF. 22 However, overall the binding to PNA was low, consistent with sialic acid capping of the VWF Olinked glycans.
| Multimeric distribution of VWF concentrates
The multimeric distribution of the VWF-containing concentrates was compared to a normal plasma pool sample ( Figure 2A A l p h a n a t e A l p h a n a t e A l p h a n a t e A l p h a n a t e O c t a n a t e O c t a n a t e O c t a n a t e O c t a n a t e 
| Free-thiol content of VWF concentrates
Recent work has demonstrated that VWF contains a number of unpaired cysteine residues and that the resultant free-thiols are important for VWF function. 20, 23 Interestingly, differences were observed in the amount of MPB bound by the different concentrates indicating differing amounts of free-thiols. While Fanhdi, Haemate P, Voncento, Optivate, 8Y, Haemoctin, and Wilate all had similar amounts of free-thiol; an ~2-fold decreased signal was seen with
Wilfactin and Alphanate and the highest amounts of free-thiols were seen in Octanate with an one-to-two-fold increased MPB binding compared to the other concentrates (Figure 3 ).
| VWF-mediated platelet adhesion to collagen under shear conditions
Next, to provide a physiological measure of function, we investigated the ability of each of the VWF-containing concentrates to mediate platelet capture to type III collagen under high shear stress using a physiological flow assay. Three concentrates, Optivate, Haemate P, and Voncento dem- (Table 2 ). Adhesion when measured at 300 seconds showed little variability between the concentrates (Figure 4 ). These adhesion data, when taken as a whole, would suggest that only the initial rate of platelet adhesion is influenced by the type of VWF containing concentrate since surface coverage values at the end of the perfusion time do not differ greatly.
| ADAMTS13 concentration in the VWF concentrates
Since some of the concentrates had an absence of HMW multimers and reduced initial rates of platelet capture we hypothesized this could be due to the concentration of ADAMTS13 in the respective concentrate. Interestingly, the ADAMTS13 concentration varied between concentrates, with Haemocitin, 8Y and Alphante having ~1.5 U/mL ADAMTS13, compared with almost an absence of ADAMTS13 in Wilate and Wilfactin. The three concentrates that had the highest initial rate of platelet capture (Haemate P, Voncento, and Optivate) had similar ADAMTS13 levels of ~0.7 U/mL (Table 1) .
| DISCUSSION
Ten commercially available VWF-containing concentrates were as- A l p h a n a t e A l p h a n a t e O c t a n a t e O c t a n a t e Each of the VWF-containing concentrates had VWF parameters assessed by VWF antigen, VWF ristocetin cofactor and VWF collagen binding assays and were found to be variable when the concentrates were reconstituted to their specified volumes according to manufacturer's instructions. However, there was a good correlation between VWF:Ag to VWF:RCo ratios and slightly less so for VWF:Ag to VWF:CB measurements (mean ratios ranged from 0.9 to 1.1 and 0.7 to 1, respectively) (r 2 ≥ 0.980). Lectin analysis demonstrated that the VWF concentrates all broadly had a similar glycan structure.
One subtle yet significant difference was noted in that 8Y had less α2-3 linked sialic acid and a corresponding increase in PNA binding potentially due to the loss of α2-3 linked sialic acid capping the T-antigen structures. It is unclear why these differences would exist; since these concentrates are derived from plasma pools it is unlikely due to the starting material and is therefore likely to be a result of the manufacturing process. 8Y is reportedly treated with solvent detergent and dry heat at 80°C for 2 hours and previous data has suggested that heating can reduce glycan detection on glycoproteins, thus this treatment approach may result in loss of some sugar structures. However, none of the other concentrates that undergo similar processing present an altered glycan structure. A mass spectrometry approach would be required to prepare a detailed glycosylation profile of each concentrate.
To test the function of the concentrates in a physiological circulating VWF 24 and contain UL-MW forms which are therefore potentially more effective hemostatically than those of plasma. 25 Since the platelets used in this study were derived from healthy individuals, one may speculate that in a VWD patient where the platelet pool of VWF is either reduced or contains VWF with VWF function this effect would be more pronounced. Using rank order by platelet deposition at 60 seconds, in As with the subtle differences in glycan structure, manufacturing differences of the concentrates as well as final formulation could theoretically contribute to qualitative differences in VWF multimeric distributions. Therefore, these were also contrasted with the rank order data in respectively. 28 It has been reported that Willfactin and Wilate contain relatively low levels of ADAMTS13 and have a VWF triplet structure similar to that of normal plasma. 29 Additionally, this study also demonstrated that Fandhi and Haemate-P had higher ADAMTS13 activity with an altered triplet structure. Alphanate is also reported to have high ADAMTS13 activity. 30 In keeping with these previously reports both Wilfactin and Wilate had the lowest ADAMTS13 concentration, while Alphanate, 8Y and
Haemoctin had the highest ADAMTS13 concentration and indeed Alphante and 8Y have been used to successfully to treat TTP. 30 While the higher ADAMTS13 concentration of Alphanate and Haemoctin may account for the lack of HMW multimers and thus reduced initial rates of platelet capture, Octanate had both lack of HMW multimers and low ADAMTS13 indicating that other currently unknown factors are may also be involved.
Another interesting observation from this study was that the free-thiol content of each of the concentrates studied differed.
VWF free-thiols have recently been shown to be important for function, while no correlation between free-thiol content and function was seen, further studies will be required to determine how this may affect the function of the VWF concentrates. As with the subtle difference in glycan content it is not clear what would cause a difference in free-thiol content, but it is most likely attributed to the manufacturing process.
The differences seen in antigen and activity assays should be borne in mind when interpreting assays used for monitoring replacement therapy in the clinical setting. This may affect dosing and administration frequency which is generally guided by post treatment and trough levels. We do not expect that there would be any significant effect on efficacy with regard to prevention or treatment of bleeding symptoms in most situations, but this is a possibility in situations where von Willebrand disease is complicated by other hemostatic abnormalities.
In conclusion, use of flow assay analysis showed that all the VWF-containing concentrates studied were equally effective at mediating platelet adhesion to human placental collagen type III coated surfaces at 300 seconds. However, several of the VWF containing concentrates lacking the highest molecular weight VWF multimers demonstrated a reduced ability to initially mediate platelet capture to collagen surfaces at 60 seconds.
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